Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Completed · Phase 3 · Has a placebo group
Conditions studied: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
In brief
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle and physical activity. The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor. * At 6 of the visits participants will have blood samples taken. * At 5 of the visits participants will be asked to fill in a questionnaire * At 4 of the visits participants will have to do a 6-minute walking test * At 3 of the visits participants will have a test to check the heart. * participants will have their eyes checked before or at the start of the study and at the end of the study Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Key facts
- Study ID
- NCT04916470
- Run by
- Novo Nordisk A/S
- People needed
- 617
- Starts
- 2021-06-15
- Expected to finish
- 2023-10-11
- Last updated by the study team
- 2025-11-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Body mass index (BMI) greater than or equal to 30.0 kg/m\^2
- New York Heart Association (NYHA) Class II-IV
- Left ventricular ejection fraction (LVEF) greater than or equal to 45% at screening
- Diagnosed with T2D greater than or equal to 90 days prior to the day of screening
- HbA1c of below or equal to 10.0% as measured at the screening visit
You may not qualify if…
- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Where it is running
- Mobile Heart Specialists — Mobile, Alabama, United States
- National Heart Institute Cal — Beverly Hills, California, United States
- John Muir Physicians Network — Concord, California, United States
- Valley Clinical Trials — Covina, California, United States
- Keck Medical Center of USC - Outpatient Clinic — Los Angeles, California, United States
- Valley Clinical Trials, Inc. — Northridge, California, United States
- Lundquist Inst-Biomed Innovtn — Torrance, California, United States
- New West Physicians,Inc. — Golden, Colorado, United States
- Excel Med Ctr Clinical Trials — Boca Raton, Florida, United States
- Bay Area Cardiology Associates, P.A. — Brandon, Florida, United States
- Baptist Heart Specialists_Jacksonville — Jacksonville, Florida, United States
- CV Res Ctr of S Florida — Miami, Florida, United States
- Endeavor Health Clinical Operations-NCH — Arlington Heights, Illinois, United States
- Endeavor Health Glenbook Hosp — Evanston, Illinois, United States
- Northwestern University_Chicago_0 — Evanston, Illinois, United States
- Chicago Medical Research LLC — Hazel Crest, Illinois, United States
- Deaconess Specialty Physicians — Evansville, Indiana, United States
- Ascension St. Vincent Medical Group — Indianapolis, Indiana, United States
- Cardiovascular Rsrch of NW_IN — Munster, Indiana, United States
- Cotton-O'Neil Heart Center — Topeka, Kansas, United States
- Baptist Health Woodland — Elizabethtown, Kentucky, United States
- The Research Group of Lexington LLC — Lexington, Kentucky, United States
- Baptist Health Louisville — Louisville, Kentucky, United States
- Grace Research, LLC — Bossier City, Louisiana, United States
- Eastern Shore Rsrch Inst, LLC — Fairhope, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.